BRPI0905725A2 - vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduo - Google Patents

vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduo

Info

Publication number
BRPI0905725A2
BRPI0905725A2 BRPI0905725A BRPI0905725A BRPI0905725A2 BR PI0905725 A2 BRPI0905725 A2 BR PI0905725A2 BR PI0905725 A BRPI0905725 A BR PI0905725A BR PI0905725 A BRPI0905725 A BR PI0905725A BR PI0905725 A2 BRPI0905725 A2 BR PI0905725A2
Authority
BR
Brazil
Prior art keywords
vaccine
create
immune response
pharmaceutical packaging
individual tissue
Prior art date
Application number
BRPI0905725A
Other languages
English (en)
Inventor
Bonnie B Plikaytis
Mani Cheruvu
Rama Roa Amara
Suraj Sable
Thomas M Shinnick
Original Assignee
Univ Emory
Us Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory, Us Government filed Critical Univ Emory
Publication of BRPI0905725A2 publication Critical patent/BRPI0905725A2/pt
Publication of BRPI0905725B1 publication Critical patent/BRPI0905725B1/pt
Publication of BRPI0905725B8 publication Critical patent/BRPI0905725B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0905725A 2008-01-11 2009-01-12 vacina e embalagem farmacêutica BRPI0905725B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2057308P 2008-01-11 2008-01-11
US61/020,573 2008-01-11
PCT/US2009/030754 WO2009089535A2 (en) 2008-01-11 2009-01-12 Polypeptide vaccine and vaccination strategy against mycobacterium

Publications (3)

Publication Number Publication Date
BRPI0905725A2 true BRPI0905725A2 (pt) 2015-12-01
BRPI0905725B1 BRPI0905725B1 (pt) 2020-12-29
BRPI0905725B8 BRPI0905725B8 (pt) 2021-05-25

Family

ID=40853787

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905725A BRPI0905725B8 (pt) 2008-01-11 2009-01-12 vacina e embalagem farmacêutica

Country Status (6)

Country Link
US (1) US8741313B2 (pt)
EP (2) EP2818178A1 (pt)
CN (1) CN101969976A (pt)
BR (1) BRPI0905725B8 (pt)
WO (1) WO2009089535A2 (pt)
ZA (1) ZA201005742B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
CN101822829B (zh) * 2010-04-07 2013-07-31 四川大学 一种用于结核病预防的重组卡介苗
CN101850111B (zh) * 2010-04-07 2013-07-31 四川大学 一种用于结核病预防的新型疫苗
EP2471511A1 (en) * 2011-01-04 2012-07-04 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
ES2631556T3 (es) 2011-01-04 2017-09-01 Archivel Farma, Sl Formulación de liposomas adecuada para tratar o prevenir la tuberculosis
PL2802345T3 (pl) 2012-01-12 2018-08-31 Archivel Farma, S.L. Szczepionka mtb-c przeciw reakcjom alergicznym
BR102012003790A2 (pt) * 2012-02-17 2014-04-22 Fundacao Butantan Cepa de mycobacterium recombinante, composição imunogênica e uso
RU2539026C1 (ru) * 2013-06-11 2015-01-10 Федеральное государственное бюджетное учреждение "Центральный научно-исследовательский институт туберкулеза" Российской академии медицинских наук РЕКОМБИНАНТНАЯ ПЛАЗМИДА pESAT6-CFP10-DBD, РЕКОМБИНАНТНЫЙ ШТАММ Escherichia coli M15 [pREP4, pESAT6-CFP10-DBD], СПОСОБ ПОЛУЧЕНИЯ, ИММОБИЛИЗАЦИИ, КОНЦЕНТРИРОВАНИЯ И ОЧИСТКИ РЕКОМБИНАНТНОГО БЕЛКА ESAT6-CFP10-DBD НА ДЕКСТРАНЕ, РЕКОМБИНАНТНЫЙ БЕЛОК ESAT6-CFP10-DBD И ИММУНОГЕННАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ БЕЛОК ESAT6-CFP10-DBD
US10414819B2 (en) 2013-08-30 2019-09-17 Longhorn Vaccines And Diagnostics, Llc Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance
US10370437B2 (en) 2013-08-30 2019-08-06 Longhorn Vaccines And Diagnostics, Llc Antibodies that modulate immunity to drug resistant and latent MTB infections
US9821047B2 (en) 2013-08-30 2017-11-21 Longhorn Vaccines And Diagnostics, Llc Enhancing immunity to tuberculosis
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2019003035A (es) 2016-09-16 2019-09-13 Infectious Disease Res Inst Vacunas que comprenden polipeptidos de mycobacterium leprae para la prevencion, el tratamiento y el diagnostico de la lepra.
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11642405B2 (en) * 2017-06-19 2023-05-09 Washington University Nanoemulsion and methods of use thereof
JP2021512144A (ja) * 2018-01-26 2021-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｃａｌｉｆｏｒｎｉａ 環状ジヌクレオチドアジュバント含有結核ワクチンの鼻腔内送達
CN112770771A (zh) * 2018-09-17 2021-05-07 丘拉提斯股份有限公司 包含干扰素基因刺激蛋白激动剂的免疫佐剂及疫苗组合物
KR102317403B1 (ko) * 2019-01-28 2021-10-29 주식회사 바이오앱 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
CN110240637A (zh) * 2019-06-04 2019-09-17 华中农业大学 牛分枝杆菌免疫相关的分子伴侣蛋白GroEL2及其编码基因与应用
CN110354098B (zh) * 2019-07-23 2021-01-05 中国农业大学 重组蛋白cfp-10纳米颗粒的制备及应用
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2022066926A1 (en) * 2020-09-23 2022-03-31 The General Hospital Corporation Bcg vaccinations for prevention of covid-19 and other infectious diseases
CN114404582B (zh) * 2021-12-20 2023-08-11 南京鼓楼医院 通过分枝杆菌特异性免疫治疗肿瘤的方法及使用的抗原肽

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196191A (en) 1975-09-29 1980-04-01 Burroughs Wellcome Co. Biological preparations
GB9525083D0 (en) 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US7037510B2 (en) * 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
EP1105096B1 (en) 1998-08-19 2003-10-29 Skyepharma Canada Inc. Injectable aqueous dispersions of propofol
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
CA2407154A1 (en) 2000-04-27 2001-11-01 Verion, Inc Zero order release and temperature-controlled microcapsules and process for the preparation thereof
US6368602B1 (en) 2000-06-16 2002-04-09 Hadasit Medical Research Services And Development Ltd Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine
US7288261B2 (en) * 2000-07-10 2007-10-30 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
US6541030B2 (en) 2000-09-27 2003-04-01 Verion Inc. Instant water dissolvable encapsulate and process
EP1343821A2 (en) 2000-11-09 2003-09-17 Immunolex Laboratories Method of producing antibodies by immunization with conjugates of molecules coupled to charge-modified proteins
FR2818647B1 (fr) * 2000-12-21 2006-09-29 Pasteur Institut Glycopeptides immunogenes, criblage, preparation et applications
WO2002058633A2 (en) 2001-01-23 2002-08-01 Massachusetts Institute Of Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
US7538206B2 (en) 2001-02-22 2009-05-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2001271554B2 (en) * 2001-06-21 2009-03-12 New York University Mycobacterial proteins as early antigens for serodiagnosis and vaccines
EP1463526A4 (en) * 2001-08-02 2006-08-30 Univ New York EARLY DETECTION OF MYCOBACTERIAL DISEASES USING PEPTIDES
US20050075298A1 (en) 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US20040009937A1 (en) 2002-01-31 2004-01-15 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the respiratory system
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
JP4662925B2 (ja) 2003-04-23 2011-03-30 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 改善された効率を有する結核ワクチン
GB0323965D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
WO2005061534A2 (en) * 2003-12-23 2005-07-07 Statens Serum Institut Improved tuberculosis vaccines
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
KR100609813B1 (ko) * 2005-02-24 2006-08-08 학교법인연세대학교 결핵 예방 백신
EP2380589A3 (en) 2005-06-23 2012-09-12 Statens Serum Institut Improved tuberculosis vaccines

Also Published As

Publication number Publication date
US8741313B2 (en) 2014-06-03
EP2818178A1 (en) 2014-12-31
ZA201005742B (en) 2011-04-28
US20110027349A1 (en) 2011-02-03
WO2009089535A2 (en) 2009-07-16
BRPI0905725B8 (pt) 2021-05-25
WO2009089535A3 (en) 2009-10-01
CN101969976A (zh) 2011-02-09
BRPI0905725B1 (pt) 2020-12-29
EP2244720A2 (en) 2010-11-03
EP2244720A4 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
BRPI0905725A2 (pt) vacina, embalagem farmacêutica e processo para criar uma resposta imune em tecido de indivíduo
PT2590976E (pt) Derivados da imidazopiridina, seu processo de preparação e sua utilização terapêutica
BR112012019757A2 (pt) composição imunogênica, e, método para induzir uma resposta imune a um polissacarídeo capsular
BRPI0914493A2 (pt) transportador e método para girar um artigo
IL248607A (en) Methods and compositions for immunization against virus
BRPI1011404A2 (pt) mutantes e usos dos mesmos
BRPI0918261A2 (pt) processos e sistema de processamento de dados para controlar peso corporal, bem como processo e sistema de processamento de dados para selecionar um produto alimentício com base no efeito do produto alimentício sobre a saúde de um ser humano
BR112013024402A2 (pt) processo para produtos terapêuticos encapsulados e usos dos mesmos
BRPI0920283A2 (pt) composição e método para induzir resposta imunológica humoral
BRPI0920282A2 (pt) composição e método para induzir resposta imunológica humoral
BR112012001172A2 (pt) artigo, e, método
FI20085760A0 (fi) Muunnettu komposiittituote ja menetelmä sen valmistamiseksi
BRPI0818477A2 (pt) Dc-sign, icam-3 e lsectin porcinos e usos dos mesmos
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
EP2318430A4 (en) POLYVALENT VACCINE
BR112012026848A2 (pt) suplemento alimentar ou medicinal e método para induzir saciedade em um indivíduo
EP2387416A4 (en) PURIFIED PLASMODIUM AND VACCINE COMPOSITIONS
BRPI0922190A2 (pt) Ácidos insaturados para proteção do desbotamento das cores provenientes de fontes naturais utilizadas em produtos de bebida
EG26636A (en) Beet processing process and unit
BRPI1007721A2 (pt) composição de vacina para induzir uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolada e método para induzir uma resposta imunológica para um rotavírus em um indivíduo
BRPI1007041A2 (pt) Suplementos nutricionais para indivíduos com +50 para melhorar a vitalidade, imunidade, saúde dos olhos e ossos
BRPI0919485A2 (pt) vacinas, antígenos, composições de plasmodium e métodos
FI20095500L (fi) Tuote ja menetelmä sen valmistamiseksi
BRPI1010086A2 (pt) método e produtos para tratamento de doenças
FI20090142A0 (fi) Uudet menetelmät ja tuotteet

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF